A REAL-WORLD OBSERVATIONAL STUDY OF ETELCALCETIDE USE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN EUROPE

被引：0

作者：

Louie, Karly ^{[1
]}

Papadopoulou, Dorothea ^{[2
]}

Hoffmann, Maxime ^{[3
]}

Escola, Joaquin Manrique ^{[4
]}

Kohnle, Matthias ^{[5
]}

Cejka, Daniel ^{[6
]}

Piccoli, Giorgina ^{[7
,8
]}

Rix, Marianne ^{[9
]}

Boots, Johannes ^{[10
]}

Pernat, Andreja Marn ^{[11
]}

Torregrosa, Vicente ^{[12
]}

Tsirtsonis, Kate ^{[1
]}

Fouqueray, Bruno ^{[13
]}

Floege, Juergen ^{[14
]}

机构：

[1] Amgen Lth, Uxbridge, Middx, England

[2] Papageorgiou Hosp, Dept Nephrol, Thessaloniki, Greece

[3] Private Hosp La Louviere Ramsay Healthcare, Dept Nephrol & Dialysis, Lille, France

[4] Complejo Hosp Navarra, Nephrol Serv, Pamplona, Spain

[5] Nephrol Zentrum Mettmann, Mettmann, Germany

[6] Ordensklinikum Linz Elisabethinen, Dept Med 3, Nephrol, Transpantat Med,Rheumatol,Geriatr, Linz, Austria

[7] Ctr Hosp Le Mans, Le Mans, France

[8] Univ Torino, Turin, Italy

[9] Univ Hosp Copenhagen, Rigshosp, Dept Nephrol, Copenhagen, Denmark

[10] Maasstad Hosp, Dept Internal Med & Nephrol, Rotterdam, Netherlands

[11] Univ Med Ctr, Ljubljana, Slovenia

[12] Univ Barcelona, Hosp Clin, Nephrol & Renal Transplant Dept, Barcelona, Spain

[13] Amgen GmbH, Rotkreuz, Switzerland

[14] Rhein Westfal TH Aachen, Div Nephrol, Aachen, Germany

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

P0794

引用

页码：1122 / 1122

页数：1

共 50 条

[21] EFFECTIVENESS AND SAFETY OF ETELCALCETIDE IN THE LONG TERM IN CLINICAL PRACTICE IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
Diaz Campillejo, Rosa
Calero Cendrero, Rosa Maria Ruiz
Olivera Azevedo, Lilia
Rodriguez Sabillon, Jorge Alberto
Ruiz Jimenez, Belen
Fernandez Solis, Maria Antonia
Galan Gonzalez, Maria Josefa
Cancho Castellano, Barbara
Hidalgo Barquero, Maria Victoria Martin
Barroso-Hernandez, Sergio
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1746 - 1746
[22] LONG-TERM EFFICACY AND SAFETY OF ETELCALCETIDE IN HEMODIALYSIS PATIENTS WITH SEVERE SECONDARY HYPERPARATHYROIDISM
Massimetti, Carlo
Micarelli, David
Feriozzi, Sandro
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1717 - 1717
[23] One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
Bushinsky, David A.
Chertow, Glenn M.
Cheng, Sunfa
Deng, Hongjie
Kopyt, Nelson
Martin, Kevin J.
Rastogi, Anjay
Urena-Torres, Pablo
Vervloet, Marc
Block, Geoffrey A.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (10) : 1769 - 1778
[24] Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
Wolf, Myles
Block, Geoffrey A.
Chertow, Glenn M.
Cooper, Kerry
Fouqueray, Bruno
Moe, Sharon M.
Sun, Yan
Tomlin, Holly
Vervloet, Marc
Oberbauer, Rainer
CLINICAL KIDNEY JOURNAL, 2020, 13 (01) : 75 - 84
[25] EXPERIENCES WITH INTRAVENOUS ETELCALCETIDE IN LONG-TERM HEMODIALYSIS PATIENTS WITH SEVERE SECONDARY HYPERPARATHYROIDISM
Pernat, Andreja Marn
Gubensek, Jakob
Cede, Ana Zupunski
Knap, Bojan
Persic, Vanja
Trampuz, Barbara Vajdic
Ponikvar, Jadranka Buturovic
Ponikvar, Rafael
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
[26] EFFECT OF SWITCHING FROM CINACALCET TO ETELCALCETIDE ON SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH HEMODIALYSIS; ESCORT TRIAL
Kurokawa, Yuka
Kaida, Yusuke
Yano, Junko
Takamiya, Yoshimi
Otome, Takaomi
Sugiyama, Miki
Kojima, Aki
Kumabe, Yuri
Ito, Sakuya
Kodama, Goh
Nakamura, Nao
Moriyama, Tomofumi
Minami, Aki
Nagata, Akiko
Nakayama, Yosuke
Shibata, Ryo
Hazama, Takuma
Fukami, Kei
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 243 - 243
[27] Treatment of secondary hyperparathyroidism in hemodialysis patients: a comparison between two Italian centers to evaluate real-world guideline implementation
Malberti, Fabio
Possenti, Stefano
Pecchini, Paola
Lucca, Bernardo
Marchi, Gianluca
Zubani, Roberto
Chiarelli, Giusy
Manenti, Chiara
Foramitti, Marina
Alberici, Federico
JOURNAL OF NEPHROLOGY, 2025,
[28] IMPACT OF ETELCALCETIDE ON FGF23 LEVELS DURING THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON HEMODIALYSIS
Wolf, Myles
Block, Geoffrey
Chertow, Glenn
Cooper, Kerry
Fouqueray, Bruno
Moe, Sharon
Sun, Yan
Tomlin, Holly
Vervloet, Marc
Oberbauer, Rainer
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
[29] Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial
Kurokawa, Yuka
Kaida, Yusuke
Hazama, Takuma
Nakayama, Yosuke
Otome, Takaomi
Shibata, Ryo
Ito, Sakuya
Kodama, Goh
Nakamura, Nao
Kambe, Takatoshi
Moriyama, Tomofumi
Nagata, Akiko
Minami, Aki
Ando, Ryotaro
Wada, Yoshifumi
Sugiyama, Miki
Usui, Michiaki
Chiba, Michio
Moriyama, Atsuo
Ohara, Atsuko
Miyazaki, Hiroshi
Kakuma, Tatsuyuki
Fukami, Kei
RENAL REPLACEMENT THERAPY, 2020, 6 (01)
[30] Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
Friedl, Claudia
Zitt, Emanuel
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1589 - 1598

← 1 2 3 4 5 →